Mammalian target of rapamycin signaling inhibition ameliorates vascular calcification via Klotho upregulation

Kidney International

Volumn 88, Issue 4, 2015, Pages 711-721

  Zhao, Yang ^a   Zhao, Ming Ming ^a   Cai, Yan ^a   Zheng, Ming Fei ^b   Sun, Wei Liang ^a   Zhang, Song Yang ^a   Kong, Wei ^a   Gu, Jun ^c   Wang, Xian ^a   Xu, Ming Jiang ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b Beijing no 6 Hospital   (China)

^c PEKING UNIVERSITY   (China)

Author keywords

aging; chronic renal failure; inorganic phosphate; vascular smooth muscle cell

Indexed keywords

KLOTHO PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; PHOSPHATE; RAPAMYCIN; SMALL INTERFERING RNA; BETA GLUCURONIDASE; MTOR PROTEIN, MOUSE; PROTEIN KINASE INHIBITOR; TARGET OF RAPAMYCIN KINASE; TUBEROUS SCLEROSIS COMPLEX 1 PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA WALL; APOPTOSIS; ARTICLE; AUTOPHAGY; BLOOD VESSEL CALCIFICATION; BONE DEVELOPMENT; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; KLOTHO GENE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SIGNAL TRANSDUCTION; UPREGULATION; VASCULAR SMOOTH MUSCLE CELL; VASCULARIZATION; ABDOMINAL AORTA; ANIMAL; ANTAGONISTS AND INHIBITORS; AORTIC DISEASES; C57BL MOUSE; CELL CULTURE; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETIC TRANSFECTION; GENETICS; KIDNEY FAILURE, CHRONIC; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PHENOTYPE; RNA INTERFERENCE; SMOOTH MUSCLE CELL; THORACIC AORTA; TIME FACTOR; VASCULAR CALCIFICATION; VASCULAR SMOOTH MUSCLE;

ANIMALS; AORTA, ABDOMINAL; AORTA, THORACIC; AORTIC DISEASES; CELLS, CULTURED; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; GLUCURONIDASE; HUMANS; KIDNEY FAILURE, CHRONIC; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; OSTEOGENESIS; PHENOTYPE; PROTEIN KINASE INHIBITORS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SIROLIMUS; TIME FACTORS; TOR SERINE-THREONINE KINASES; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS; VASCULAR CALCIFICATION;

EID: 84942989958     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2015.160     Document Type: Article

References (43)

1. Braun N, Kimmel M, Alscher MD. Extraosseous calcification in chronic renal failure. Am J Dermatopathol 2011; 33: 634.
2. Campean V, Neureiter D, Varga I et al. Atherosclerosis and vascular calcification in chronic renal failure. Kidney Blood Press Res 2005; 28: 280-289.
3. Neven E, D'Haese PC. Vascular calcification in chronic renal failure: what have we learned from animal studies? Circ Res 2011; 108: 249-264.
4. Neven E, Dauwe S, De Broe ME et al. Endochondral bone formation is involved in media calcification in rats and in men. Kidney Int 2007; 72: 574-581.
5. Steitz SA, Speer MY, Curinga G et al. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res 2001; 89: 1147-1154.
6. Shanahan CM, Crouthamel MH, Kapustin A et al. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res 2011; 109: 697-711.
7. Jono S, McKee MD, Murry CE et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000; 87: E10-E17.
8. Shroff R. Phosphate is a vascular toxin. Pediatr Nephrol 2013; 28: 583-593.
9. Dai XY, Zhao MM, Cai Y et al. Phosphate-induced autophagy counteracts vascular calcification by reducing matrix vesicle release. Kidney Int 2013; 83: 1042-1051.
10. Zhao MM, Xu MJ, Cai Y et al. Mitochondrial reactive oxygen species promote p65 nuclear translocation mediating high-phosphate-induced vascular calcification in vitro and in vivo. Kidney Int 2011; 79: 1071-1079.
11. Polak P, Hall MN. mTOR and the control of whole body metabolism. Curr Opin Cell Biol 2009; 21: 209-218.
12. Pakala R, Stabile E, Jang GJ et al. Rapamycin attenuates atherosclerotic plaque progression in apolipoprotein E knockout mice: inhibitory effect on monocyte chemotaxis. J Cardiovasc Pharmacol 2005; 46: 481-486.
13. Chen WQ, Zhong L, Zhang L et al. Oral rapamycin attenuates inflammation and enhances stability of atherosclerotic plaques in rabbits independent of serum lipid levels. Br J Pharmacol 2009; 156: 941-951.
14. Tataranni T, Biondi G, Cariello M et al. Rapamycin-induced hypophosphatemia and insulin resistance are associated with mTORC2 activation and Klotho expression. Am J Transplant 2011; 11: 1656-1664.
15. Yeh LC, Ma X, Ford JJ et al. Rapamycin inhibits BMP-7-induced osteogenic and lipogenic marker expressions in fetal rat calvarial cells. J Cell Biochem 2013; 114: 1760-1771.
16. Shoba LN, Lee JC. Inhibition of phosphatidylinositol 3-kinase and p70S6 kinase blocks osteogenic protein-1 induction of alkaline phosphatase activity in fetal rat calvaria cells. J Cell Biochem 2003; 88: 1247-1255.
17. Singha UK, Jiang Y, Yu S et al. Rapamycin inhibits osteoblast proliferation and differentiation in MC3T3-E1 cells and primary mouse bone marrow stromal cells. J Cell Biochem 2008; 103: 434-446.
18. Xian L, Wu X, Pang L et al. Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells. Nat Med 2012; 18: 1095-1101.
19. Ohkawa S, Yanagida M, Uchikawa T et al. Attenuation of the activated mammalian target of rapamycin pathway might be associated with renal function reserve by a low-protein diet in the rat remnant kidney model. Nutr Res 2013; 33: 761-771.
20. Lieberthal W, Levine JS. The role of the mammalian target of rapamycin (mTOR) in renal disease. J Am Soc Nephrol 2009; 20: 2493-2502.
21. Hu MC, Shi M, Zhang J et al. Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol 2011; 22: 124-136.
22. Gui T, Zhou G, Sun Y et al. MicroRNAs that target Ca(2+) transporters are involved in vascular smooth muscle cell calcification. Lab Invest 2012; 92: 1250-1259.
23. Voelkl J, Alesutan I, Leibrock CB et al. Spironolactone ameliorates PIT1-dependent vascular osteoinduction in klotho-hypomorphic mice. J Clin Invest 2013; 123: 812-822.
24. Tsang CK, Qi H, Liu LF et al. Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov Today 2007; 12: 112-124.
25. Adeney KL, Siscovick DS, Ix JH et al. Association of serum phosphate with vascular and valvular calcification in moderate CKD. J Am Soc Nephrol 2009; 20: 381-387.
26. Speer MY, Yang HY, Brabb T et al. Smooth muscle cells give rise to osteochondrogenic precursors and chondrocytes in calcifying arteries. Circ Res 2009; 104: 733-741.
27. Byon CH, Javed A, Dai Q et al. Oxidative stress induces vascular calcification through modulation of the osteogenic transcription factor Runx2 by AKT signaling. J Biol Chem 2008; 283: 15319-15327.
28. Zhao G, Xu MJ, Zhao MM et al. Activation of nuclear factor-kappa B accelerates vascular calcification by inhibiting ankylosis protein homolog expression. Kidney Int 2012; 82: 34-44.
29. Hao H, Hirota S, Ishibashi-Ueda H et al. Expression of matrix Gla protein and osteonectin mRNA by human aortic smooth muscle cells. Cardiovasc Pathol 2004; 13: 195-202.
30. Lee KW, Yook JY, Son MY et al. Rapamycin promotes the osteoblastic differentiation of human embryonic stem cells by blocking the mTOR pathway and stimulating the BMP/Smad pathway. Stem Cells Dev 2010; 19: 557-568.
31. Ogawa T, Tokuda M, Tomizawa K et al. Osteoblastic differentiation is enhanced by rapamycin in rat osteoblast-like osteosarcoma (ROS 17/2. 8) cells. Biochem Biophys Res Commun 1998; 249: 226-230.
32. Kuro-o M. Klotho. Pflugers Arch 2010; 459: 333-343.
33. Liu F, Wu S, Ren H et al. Klotho suppresses RIG-I-mediated senescenceassociated inflammation. Nat Cell Biol 2011; 13: 254-262.
34. Lim K, Lu TS, Molostvov G et al. Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23. Circulation 2012; 125: 2243-2255.
35. Hu MC, Kuro-o M, Moe OW. Secreted klotho and chronic kidney disease. Adv Exp Med Biol 2012; 728: 126-157.
36. Kempe DS, Dermaku-Sopjani M, Fröhlich H et al. Rapamycin-induced phosphaturia. Nephrol Dial Transplant 2010; 25: 2938-2944.
37. Haller M, Amatschek S, Wilflingseder J et al. Sirolimus induced phosphaturia is not caused by inhibition of renal apical sodium phosphate cotransporters. PLoS One 2012; 7: e39229.
38. Powers RW 3rd, Kaeberlein M, Caldwell SD et al. Extension of chronological life span in yeast by decreased TOR pathway signaling. Genes Dev 2006; 20: 174-184.
39. Harrison DE, Strong R, Sharp ZD et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009; 460: 392-395.
40. Selman C, Tullet JM, Wieser D et al. Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science 2009; 326: 140-144.
41. Tamagaki K, Yuan Q, Ohkawa H et al. Severe hyperparathyroidism with bone abnormalities and metastatic calcification in rats with adenineinduced uraemia. Nephrol Dial Transplant 2006; 21: 651-659.
42. Cai Y, Xu MJ, Teng X et al. Intermedin inhibits vascular calcification by increasing the level of matrix gamma-carboxyglutamic acid protein. Cardiovasc Res 2010; 85: 864-873.
43. Kuro-o M, Matsumura Y, Aizawa H et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997; 390: 45-51.